Atlas Trials

Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

Clinical trial NCT06082934 · RECRUITING

Trial details

NCT number
NCT06082934
Sponsor
Xijing Hospital
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
Start date
2023-11-01
Primary completion
2026-11-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.